Literature DB >> 17764823

Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials.

Laurence Collette.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17764823     DOI： 10.1016/j.eururo.2007.08.041

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  12 in total

1.  CYP17 polymorphisms and prostate cancer outcomes.

Authors:  Jonathan L Wright; Erika M Kwon; Daniel W Lin; Suzanne Kolb; Joseph S Koopmeiners; Ziding Feng; Elaine A Ostrander; Janet L Stanford
Journal:  Prostate       Date:  2010-07-01       Impact factor: 4.104

2.  Dynamic prediction of metastases after radical prostatectomy for prostate cancer.

Authors:  Brant A Inman; Igor Frank; Stephen A Boorjian; Joseph W Akornor; R Jeffrey Karnes; Bradley C Leibovich; Michael L Blute; Eric J Bergstralh
Journal:  BJU Int       Date:  2011-05-26       Impact factor: 5.588

3.  Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality.

Authors:  Jonathan L Wright; Bruce L Dalkin; Lawrence D True; William J Ellis; Janet L Stanford; Paul H Lange; Daniel W Lin
Journal:  J Urol       Date:  2010-06       Impact factor: 7.450

4.  Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.

Authors:  Jonathan L Wright; Erika M Kwon; Elaine A Ostrander; R Bruce Montgomery; Daniel W Lin; Robert Vessella; Janet L Stanford; Elahe A Mostaghel
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-01-25       Impact factor: 4.254

5.  Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP Trial).

Authors:  Mei Lu; Svend O Freytag; Hans Stricker; Jae Ho Kim; Kenneth Barton; Benjamin Movsas
Journal:  Contemp Clin Trials       Date:  2011-02-12       Impact factor: 2.226

6.  A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1).

Authors:  Marijo Bilusic; Nicole J Toney; Renee N Donahue; Susan Wroblewski; Matthew Zibelman; Pooja Ghatalia; Eric A Ross; Fatima Karzai; Ravi A Madan; William L Dahut; James L Gulley; Jeffrey Schlom; Elizabeth R Plimack; Daniel M Geynisman
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-01-25       Impact factor: 5.455

7.  Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort.

Authors:  Jonathan L Wright; Claudia A Salinas; Daniel W Lin; Suzanne Kolb; Joseph Koopmeiners; Ziding Feng; Janet L Stanford
Journal:  J Urol       Date:  2009-12       Impact factor: 7.450

8.  Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.

Authors:  Nicolas Methy; Laurent Bedenne; Franck Bonnetain
Journal:  BMC Cancer       Date:  2010-06-10       Impact factor: 4.430

9.  Visceral disease in castration-resistant prostate cancer.

Authors:  C Pezaro; A Omlin; D Lorente; D Nava Rodrigues; R Ferraldeschi; D Bianchini; D Mukherji; R Riisnaes; A Altavilla; M Crespo; N Tunariu; J de Bono; G Attard
Journal:  Eur Urol       Date:  2013-11-22       Impact factor: 20.096

10.  Biochemical recurrence risk factors in surgically treated high and very high-risk prostate tumors.

Authors:  Alfredo Aguilera; Beatriz Bañuelos; Jesús Díez; Jose María Alonso-Dorrego; Jesus Cisneros; Javier Peña
Journal:  Cent European J Urol       Date:  2015-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.